Skip to main content

Table 1 Characteristics of study participants by study and overall

From: Evaluating the performance of propensity score matching based approaches in individual patient data meta-analysis

Study N Age mean (SD) Male N. (%) Smear N. (%) HIV N. (%) Ethionamide N. (%)
Ahujan 823 41.4 (12.0) 561 (68.2) 509 (70.8) 488 (74.4) 394 (47.9)
Avenda 72 36.3 (15.3) 43 (59.7) 67 (93.1) 1 (1.4) 13 (18.1)
Burgos 48 47.2 (14.8) 32 (66.7) 36 (75.0) 11 (22.9) 17 (35.4)
Chan 203 42.0 (14.4) 116 (57.1) 203 (100.0) 0 (0.0) 124 (61.1)
Chiang 125 46.1 (15.2) 90 (72.0) 109 (93.2) 0 (0.0) 57 (45.6)
Cox 77 36.9 (11.2) 47 (61.0) 76 (98.7) 0 (0.0) 72 (93.5)
Garcia 47 47.6 (16.4) 26 (55.3) 42 (89.4) 0 (0.0) 22 (46.8)
Granic 104 40.3 (19.5) 61 (58.7) 75 (74.3) 1 (100.0) 47 (45.2)
Koh 155 40.9 (14.4) 82 (52.9) 131 (84.5) 0 (0.0) 74 (47.7)
Lung 99 46.1 (16.2) 74 (74.7) 78 (80.4) 0 (0.0) 47 (47.5)
Migliori 101 39.4 (14.7) 61 (60.4) 80 (79.2) 6 (6.2) 46 (45.5)
Mitnic 732 31.1 (12.0) 436 (59.6) 508 (71.1) 8 (1.2) 495 (67.6)
Narita 81 40.2 (11.8) 55 (67.9) 0 (0.0) 41 (54.7) 26 (32.1)
Palmer 114 35.3 (13.7) 54 (47.4) 108 (94.7) 0 (0.0) 8 (7)
Pasvol 45 36.0 (16.7) 21 (50.0) 29 (74.4) 0 (0.0) 25 (55.6)
Pena 25 41.2 (13.3) 24 (96.0) 25 (100.0) 0 (0.0) 0 (0)
Perez 34 42.1 (12.4) 21 (61.8) 34 (100.0) 0 (0.0) 0 (0)
Quy 157 39.5 (11.4) 121 (77.1) 157 (100.0) 4 (2.5) 0 (0)
Riekstina 1027 42.3 (12.7) 780 (75.9) 269 (68.1) 32 (3.9) 0 (0)
Robert 45 41.7 (15.6) 24 (53.3) 33 (73.3) 9 (25.7) 18 (40.0)
Schaaf 39 7.0 (5.4) 20 (51.3) 9(33.3) 6 (20.7) 30 (76.9)
Seung 1427 43.9 (15.4) 117 (82.4) 142 (100.0) 0 (0.0) 0 (0)
Shim 1364 42.8 (14.9) 1014 (74.3) 927 (68.0) 1 (0.1) 0 (0)
Shin 608 35.8 (11.3) 506 (83.2) 497 (85.8) 5 (0.8) 450 (74.0)
Shirai 61 46.4 (11.9) 46 (75.4) 0 (0.0) 0 (0.0) 40 (65.6)
Tabars 43 44.4 (19.1) 27 (62.8) 42 (97.7) 0 (0.0) 0 (0)
Tupasi 170 39.2 (12.4) 106 (62.4) 107 (67.7) 0 (0.0) 40 (23.5)
Vander 43 32.9 (18.3) 32 (74.4) 0(0.0) 0 (0.0) 1 (2.3)
Vander 2211 36.6 (10.8) 1383 (62.6) 1390 (69.7) 571 (38.4) 2211 (100)
Viiklepp 284 43.0 (13.6) 201 (70.8) 153 (53.9) 9 (3.4) 0 (0)
Yimkim 211 39.3 (15.8) 124 (58.8) 0 (0.0) 0 (0.0) 0 (0)
Median 104 41 63 75 0 41
P25 48 37 59 68 0 0
P75 207 43 74 94 5 51
  1. N.(%): The number and percentage of patients in each study.
  2. Median, P25 and P75 indicates the median, 25th and 75th Percentiles which have been calculated for the number of patients, mean age of patients, proportion of male patients, proportion of smear status, HIV status across studies, and proportion of treatment Ethionamide